All In Biotech

Drug Trial Radar · NCT05252585

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Phase IV, Prospective Single Arm Study of Safety and Efficacy of Votubia (Everolimus) in Taiwanese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

May 1, 2023

Primary completion

Oct 13, 2026

Study completion Oct 13, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.

Conditions

  • Renal Angiomyolipoma

Interventions

  • EverolimusDrug

    Everolimus tablets for oral use. The recommended everolimus starting dose will be 10 mg orally taken once daily for all patients, except for those with impaired liver function, for whom the everolimus dose will be: * Child-Pugh grade A: 7.5 mg once daily (for patients with mild hepatic impairment) * Child-Pugh grade B: 5.0 mg once daily (for patients with moderate hepatic impairment)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with adverse events (AEs), Serious AEs (SAEs) and AEs of special interest (AESI)Time frame: From first dose of study treatment up to 56 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Taipei, Taiwan

  • Novartis Investigative Site

    Taoyuan, Taiwan

  • Novartis Investigative Site

    Taichung, Taiwan ROC, Taiwan

  • Novartis Investigative Site

    Taoyuan, Taiwan ROC, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.